DGAP-News: Alphaform AG / Key word(s): Half Year Results
Alphaform AG: Interim Report 2nd Quarter 2012
10.08.2012 / 11:28
---------------------------------------------------------------------
Press release
First half of year 2012:
Upwards trend continues at Alphaform
Revenue climbs by 10.1% to EUR14.1 million as against the same period
of the previous year
Operating result at EUR0.4 million still clearly positive
Forecast for the business year 2012 is confirmed
Feldkirchen, 10th August 2012 - Alphaform AG, as specialist in additive
manufacturing and a leading company in the production of orthopaedic
implants and instruments, increased the group revenue in the first half of
the year 2012 by 10.1% up to EUR14.1 million compared to the previous year
(first half of year 2011: EUR12.8 million). After the net result in the
first half of the year 2011 was still at EUR-0.25 million, it rose
considerably to positive EUR0.4 million. EBITDA (resulted from interest,
taxes and deductions) climbed from EUR0.55 million in the first half of the
year 2011 to EUR1.2 million in the same reporting period in 2012.
The cash flow from operating activities in the Alphaform Group increased in
the first half of the year 2012 to EUR-0.1 million, after EUR-1.0 million
in the same period in 2011. The cause for this increase, is the improved
operational performance in the whole group. This fact is also reflected on
an improved gross profit margin, which climbed by 5.6% up to 71.7% (first
half of the year 2011: 66.1%). Alphaform earnings per share amounted to
EUR0.07 in the first six months of the year 2012, after EUR-0.05 in the
first half of the year 2011.
Premium automotive manufacturers bring order boom
The still high demand for prototypes caused by developing activities in the
automotive industry, specially the new developments in the premium segment,
as well as electric cars, provides for high revenues in the business areas
Rapid Prototyping and Rapid Tooling since already the second quarter of
2011. Although the economical situation in the automotive industry is
generally decreasing, premium automotive manufacturers still reached good
results and they confirmed the strategy of the technology and model
offensive. For this, Alphaform still expects constant revenues in this
area.
Medical technology with significantly improved results
In the medical technology business area, revenues slightly rose again in
the second quarter of 2012, after they reduced considerably in the first
quarter compared to the previous year. Implants post processing, which
usually have been subcontracted, were insourced at the beginning of the
year by the customer himself. This insourcing was reasonable for the
revenues reduction. The on-going enhancement measures program reached
further costs savings, so that the revenue margin climbed to 3% in the
second quarter. Since July, a casting specialist with restructuring
experience is leading the subsidiary MediMet. The previous manager director
and founder of MediMet remains at our side as advisor. We want to raise the
revenue marge to 10% until the business year 2014. The order situation and
customer relations keep intact, so that Alphaform can count on a constant
development of the medical technology area, and the goal of a sustainable
results improvement will be reached in this year.
The development of the foreign subsidiaries in Scandinavia and the UK also
continues being positive. In the first half of the year 2012, a profitable
growth of 20.7% in Scandinavia and 67.7% in the UK could be reached in all
the activities, compared to the period of the previous year. The Claho
subsidiary is operating at good capacity, the same as in the previous year.
Forecast for the business year 2012 is confirmed
Alphaform expects for the rest of the business year 2012 stable revenues at
the same level of the previous year. Prototyping business probably might
continue taking advantage of the intensive developing activity in the
premium automotive sector. A constant market development is expected in the
medical implants and instruments area, in which revenues and customer base
largely remain the same. Positive drive results from the enhancement
measures program in the medical technology and from the improved product
mix in prototyping. For the complete year 2012, Alphaform AG forecasts a
slightly higher revenue compared to the previous year and a positive
consolidated net result as well, as far as the targeted industries of the
company continue developing positive - considering the worldwide uncertain
economic situation.
Key figures of the Alphaform Group
|[![CDATA[|[pre|]]]|]
EURm 1st half
year
2012 2011 Change
Revenues 14.083 12.790 10.1 %
EBITDA 1.161 0.549 111.5%
EBIT 0.508 -0.095 -
Earnings after taxes 0.387 -0.248 -
Earnings per share 0.07 EUR -0.05 EUR -
Equity as of 30 June (2011: 31 Dec) 12.631 12.254 3.1 %
Balance sheet total as of 30 June 20.485 20.491 0.0 %
(2011: 31 Dec)
Equity ratio (percent) 61.7 % 59.8 % 3.1 %
Free liquidity as of 30 June (2011: 1.142 1.883 -39.4%
31 Dec)
Employees Group as of 30 June (2011: 231 239 -3.3 %
31 Dec)
|[![CDATA[|[/pre|]]]|]
About Alphaform
Alphaform AG, based in Feldkirchen near Munich and founded in 1996, is a
production company for complex components and products produced in smaller
batches. Alphaform is among the European market leaders in prototyping, the
production of near-series prototypes, particularly for the automotive and
capital goods industries. The company has a leading position throughout
Europe in the manufacturing of orthopaedic implants and instruments.
Alphaform's shares are listed in the Prime Standard segment of the
Frankfurt stock exchange (code: ATF).
The core competence of Alphaform lies in its extensive application
expertise for processes and materials for the additive production of
complex prototypes, tools, individual components and small series of
plastics and metals. The company's work focuses on the orthopaedic and
medical technology, automotive, aviation and aerospace industries. There
are Alphaform subsidiaries in Germany, Finland, Sweden and the UK.
Contact:
Dr. Thomas Vetter
CEO
ALPHAFORM AG
KapellenstraÃe 10
85622 Feldkirchen
Tel.: +49 89 905002 21
Fax: +49 89 9050021021e-mail: tvetter@alphaform.de
Internet: www.alphaform.de
End of Corporate News
---------------------------------------------------------------------
10.08.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Alphaform AG
KapellenstraÃe 10
85622 Feldkirchen
Germany
Phone: +49 (0)89 905002 - 0
Fax: +49 (0)89 905002 - 90
E-mail: ir@alphaform.de
Internet: www.alphaform.de
ISIN: DE0005487953
WKN: 548795
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
181269 10.08.2012
DGAP-News: Alphaform AG: Interim Report 2nd Quarter 2012
| Source: EQS Group AG